证券代码：688382 证券简称：益方生物 公告编号：2025-030 益方生物科技（上海）股份有限公司 关于 2022 年限制性股票激励计划预留授予部分第二 个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 限制性股票拟归属数量：2.0647 万股 ? 归属股票来源：向激励对象定向发行的益方生物科技（上海）股份有 限公司（以下简称"公司"）人民币 A 股普通股股票 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划方案及履行的程序 （1）激励方式：第二类限制性股票 （2）授予数量：553.4115 万股，其中首次授予 461.1762 万股，预留授予 （3）授予价格：4.35 元/股 （4）激励人数：首次授予 71 人，预留授予合计 30 人 （5）本次激励计划首次授予的限制性股票的归属期限和归属安排具体如下： 归属期 归属安排 归属比例 自首次授予部分限制性股票授予日起 12 个月后的 第一个归属期 首个交易日起至首次授予部分限制性股票授予日起 40% 自首次授予部 ...

Core Viewpoint - The report highlights the financial performance and operational challenges faced by InventisBio, emphasizing its ongoing drug development efforts and the risks associated with being a pre-revenue biotech company [1][3][4]. Financial Performance - The company reported a revenue of 19.16 million RMB for the first half of 2025, representing a 28.85% increase compared to 14.87 million RMB in the same period last year [3]. - The total profit for the period was a loss of 119.43 million RMB, an improvement from a loss of 214.22 million RMB in the previous year [3]. - The net assets attributable to shareholders decreased by 5.12% to 171.81 million RMB from 181.08 million RMB at the end of the previous year [3]. Research and Development Focus - InventisBio is focused on developing innovative drugs targeting major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to addressing unmet clinical needs [5][19]. - The company has established various platforms for drug discovery and development, including target evaluation, molecular design, pharmacology, and clinical trial design [5][19]. - All products in the pipeline are self-developed, with global intellectual property rights, and collaborations with well-known pharmaceutical companies [7][19]. Product Pipeline - The company has two authorized products: - **Befotertinib (BPI-D0316)**: An EGFR tyrosine kinase inhibitor for treating EGFR mutation-positive non-small cell lung cancer (NSCLC) [8][9]. - **Gisoresib (D-1553)**: A KRAS G12C inhibitor for treating various cancers, including NSCLC and colorectal cancer, with ongoing international clinical trials [9][10]. - Other products in clinical trials include: - **Taragarestrant (D-0502)**: An oral selective estrogen receptor degrader for ER-positive, HER2-negative breast cancer [12][16]. - **D-0120**: A URAT1 inhibitor for treating hyperuricemia and gout, showing promising results in clinical trials [14][19]. - **D-2570**: A selective TYK2 inhibitor for treating psoriasis and other autoimmune diseases, with favorable safety and efficacy profiles [16][19]. Market Position and Strategy - The company aims to enhance its market position and international competitiveness by focusing on innovative drug development and addressing significant clinical needs [5][19]. - InventisBio's operational model involves outsourcing non-core activities to third-party service providers while maintaining control over critical research and development processes [19].

Core Viewpoint - Yifang Biotechnology (Shanghai) Co., Ltd. is an innovative drug research and development company that has not yet achieved profitability, with most of its products still in the clinical research phase, highlighting the long and capital-intensive nature of the drug development cycle [1][2][3]. Company Overview - The company has two authorized products, Beifu Tini and Gesuoleisai, which have been approved for market release, potentially improving the company's financial situation through milestone payments and sales sharing as clinical development progresses [1]. - As of the end of the reporting period, the total assets of the company were approximately 192.08 billion RMB, showing a decrease of 5.61% compared to the previous year [4]. - The net assets attributable to shareholders were approximately 171.81 billion RMB, reflecting a decrease of 5.12% year-on-year [4]. Financial Performance - The company reported an operating income of approximately 28.85 million RMB for the reporting period [4]. - The net loss attributable to shareholders was approximately 11.94 billion RMB, compared to a loss of 21.42 billion RMB in the previous year [4]. - The net profit excluding non-recurring gains and losses was approximately -10.72 billion RMB, down from -18.78 billion RMB year-on-year [4]. Research and Development - The company has a high research and development expenditure, with R&D costs accounting for 602.48% of operating income, indicating a significant investment in the development of new drugs [4]. - The company is currently engaged in multiple research projects, necessitating substantial ongoing R&D investments, which contribute to its cumulative losses [1][2]. Market and Competition - The innovative drug market is characterized by intense competition, with competitors potentially having stronger financial resources, technical capabilities, and marketing strategies [2]. - The company faces challenges in establishing a commercial sales team and gaining recognition for its products in the market, which may affect its ability to successfully commercialize its drugs [3].

证券代码：688382 证券简称：益方生物 公告编号：2025-034 益方生物科技（上海）股份有限公司 第二届董事会 2025 年第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"）第二届董事会 知已于 2025 年 8 月 16 日以书面形式发出。会议应出席董事 9 名，实际出席董 事 9 名，公司高级管理人员列席本次会议。本次会议的召集、召开程序符合 《中华人民共和国公司法》及《益方生物科技（上海）股份有限公司章程》的 有关规定。公司董事长 YAOLIN WANG（王耀林）先生召集并主持本次会议。 二、董事会会议审议情况 出席会议的董事审议通过以下议案： （一）审议通过《关于使用部分闲置募集资金进行现金管理的议案》 同意公司使用不超过人民币 10 亿元（包含本数）的暂时闲置募集资金进行 现金管理，额度使用期限自董事会审议通过之日起 12 个月内有效，在上述额度 和期限内，资金可循环滚动使用。闲置募集资金现金管理产品到期后，募集 ...

经核查，本次激励计划预留授予的2名激励对象符合《公司法》《证券法》等 法律法规、规范性文件规定的任职资格，符合《管理办法》以及本次激励计划规定 的激励对象范围，其作为本次激励计划激励对象的主体资格合法有效。根据本次激 励计划的规定，上述激励对象获授限制性股票的归属条件已成就。董事会薪酬与考 核委员会同意公司本次激励计划预留授予部分第二个归属期的归属名单。 益方生物科技（上海）股份有限公司 董事会薪酬与考核委员会 益方生物科技（上海）股份有限公司董事会薪酬与考核委员会 关于 2022 年限制性股票激励计划预留授予部分第二个归属期 归属名单的核查意见 益方生物科技（上海）股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第4号——股权激励信息披露》等相关法律、法规及规范 性文件和《益方生物科技（上海）股份有限公司章程》的有关规定，对公司2022 年限制性股票激励计划（以下简称 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-035 益方生物科技（上海）股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月8日 至2025 年 9 月 8 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 （七） 涉及公开征集股东投票权 不涉及 二、 会议审议事项 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 网络投票系统：上海证券交易所股东会网络投票 ...

Financial Performance - The company's revenue for the first half of the year reached CNY 1,916.38 million, representing a 28.85% increase compared to CNY 1,487.32 million in the same period last year[23]. - The total profit for the period was a loss of CNY 11,943.25 million, an improvement from a loss of CNY 21,421.83 million in the previous year[23]. - The net profit attributable to shareholders was also a loss of CNY 11,943.25 million, showing a similar trend as the total profit[23]. - The net cash flow from operating activities was a negative CNY 10,724.99 million, compared to a negative CNY 18,777.06 million in the previous year[23]. - The company's net assets attributable to shareholders decreased by 5.12% to CNY 171,810.22 million from CNY 181,078.32 million at the end of the previous year[23]. - The total assets decreased by 5.61% to CNY 181,296.82 million from CNY 192,081.72 million at the end of the previous year[23]. - The basic earnings per share for the period was CNY -0.21, an improvement from CNY -0.37 in the same period last year[24]. - The R&D expenditure accounted for 602.48% of revenue, a significant decrease of 802.13 percentage points compared to the previous year[25]. - The company recognized an increase in technology licensing and cooperation income during the period, contributing to the improved financial metrics[25]. - The company is expected to see a reduction in R&D expenses as the clinical trial for a specific drug is set to conclude in 2024, impacting future financials positively[25]. Product Development and Pipeline - Currently, the company has two authorized products, Beifu Tian and Gesorai, which have been approved for market, potentially improving financial conditions through milestone payments and sales sharing[3]. - The company is in the clinical development phase for several products, which have not yet entered the commercialization stage[4]. - The product pipeline includes self-developed drugs with global intellectual property rights, collaborating with well-known pharmaceutical companies like Betta Pharmaceuticals and Pfizer[32]. - The company is focused on developing innovative drugs with independent intellectual property rights aimed at global markets[3]. - The drug BPI-D0316 (Befotinib) has received approval for both first-line and second-line treatment indications for EGFR mutation-positive non-small cell lung cancer (NSCLC) in 2023, and is included in the National Medical Insurance Directory[34]. - The company has initiated Phase III clinical trials for Befotinib as adjuvant therapy for NSCLC and is conducting studies in combination with MCLA-129 for advanced NSCLC patients[34]. - The KRAS G12C inhibitor D-1553 (Gosorese) is the first domestically developed KRAS G12C inhibitor entering clinical trials, with international multi-center trials ongoing in several countries[36]. - The oral selective estrogen receptor degrader (SERD) D-0502 is in phase III clinical trials for ER-positive, HER2-negative breast cancer, with a significant patient population of approximately 75% among breast cancer cases[41]. - D-0120, a URAT1 inhibitor for treating hyperuricemia and gout, demonstrated an 80% uric acid target rate at a daily dose of 4mg in phase IIa trials[44]. - D-2570, a novel oral selective TYK2 inhibitor, is being developed for psoriasis and autoimmune diseases, with a favorable safety profile compared to existing treatments[46]. Research and Development - The company has established various platforms for drug design and evaluation, enhancing its capabilities in drug development[30]. - The company has a robust preclinical pipeline, with candidates YF087 and YF550 showing promising anti-tumor efficacy in various animal models, presented at the AACR annual meeting[49]. - The company has established a comprehensive R&D system covering the entire drug development process, including drug chemistry, pharmacology, and clinical research[50]. - The R&D team consists of 153 members, accounting for 91.07% of total employees, with an average of over 20 years of experience in multinational pharmaceutical companies[103]. - The clinical development team, led by a chief medical officer with over 20 years of experience, has efficiently advanced Gsorese into key registration clinical trials within two years[104]. - The company utilizes advanced drug design technologies, including computer-aided drug design and high-throughput screening, to enhance the success rate and reduce the development cycle of new drugs[106]. - The company has established its own pharmacokinetics and early toxicology assessment platforms to enhance drug development efficiency[107]. Market and Competitive Landscape - The competitive landscape in the innovative drug market is intense, with competitors potentially having stronger financial resources and marketing strategies[4]. - The uncertainty of entering the National Medical Insurance Directory may affect the pricing competitiveness of products in the domestic market[5]. - The global pharmaceutical market grew from $1,266.7 billion in 2018 to $1,495.0 billion in 2022, with a CAGR of 4.2%[61]. - The Chinese pharmaceutical market reached ¥1,554.1 billion in 2022, with projected CAGR of 8.1% from 2022 to 2025 and 6.0% from 2025 to 2030[64]. - The global oncology drug market increased from $110.6 billion in 2017 to $181.7 billion in 2021, with a CAGR of 13.2%[69]. - The Chinese oncology drug market grew from ¥139.4 billion in 2017 to ¥231.1 billion in 2021, with a CAGR of 13.5%[69]. - The global metabolic disease market expanded from $105.0 billion in 2018 to $160.0 billion in 2022, with a CAGR of 10.9%[73]. - The global autoimmune disease drug market was approximately $132.3 billion in 2022, expected to reach $147.3 billion by 2025, with a CAGR of 3.6% from 2022 to 2025[84]. Risks and Challenges - The company has not yet achieved profitability and has accumulated losses due to the long development cycle typical in the innovative drug research industry[3]. - The company is facing significant risks related to performance decline or losses, as ongoing research projects require substantial funding[4]. - The company is exposed to financial risks, including the need for substantial funding for clinical trials and regulatory approvals[135]. - The company is conducting international multi-center clinical trials in multiple countries, which exposes it to foreign exchange risks[135]. - The company faces industry risks due to strict regulatory oversight and potential changes in healthcare policies[136]. - The company is also at risk from macroeconomic factors and legal complexities in overseas markets[137]. Corporate Governance and Commitments - The company has committed to stabilizing its stock price post-listing for three years[157]. - The company has established a commitment to comply with relevant regulations regarding shareholding and changes in shareholding for its controlling shareholders and executives[160]. - The company will ensure that any violations of the shareholding commitments will result in the proceeds from the sale of shares being returned to the company[163]. - The company has committed to strengthening R&D and expanding its market presence while enhancing its intellectual property protection system[179]. - The company guarantees strict adherence to all public commitments disclosed in the prospectus[19].

证券代码：688382 证券简称：益方生物 公告编号：2025-031 益方生物科技（上海）股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》以及《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的相关规定， 益方生物科技（上海）股份有限公司（以下简称"公司"或"益方生物"）董事 会将 2025 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生 物科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可（2022） 682 号），公司获准向社会公开发行人民币普通股 11,500 万股，每股发行价格为 人民币 18.12 元，募集资金总额为 208,380.00 万元，扣除承销及保荐费用、发 行登记费以及累计发生的其他相关发行费用（共计人民币 101 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-029 益方生物科技（上海）股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 益方生物科技（上海）股份有限公司（以下简称"公司"）于2025年8月21 日召开第二届董事会2025年第五次会议，审议通过《关于使用部分闲置募集资 金进行现金管理的议案》，同意公司使用不超过人民币10亿元（包含本数）的 暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、保本型的理 财产品或存款类产品（包括但不限于协定性存款、结构性存款、定期存款、大 额存单、收益凭证等）。使用期限自董事会审议通过之日起12个月内有效，在 上述额度和期限内，资金可循环滚动使用。闲置募集资金现金管理到期后将归 还至募集资金专户。保荐机构对本事项出具了明确的核查意见。具体情况公告 如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于2022年4月1 日出具的《关于同意益方生物科技（上海）股份有限公司首次公开发行股 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-033 益方生物科技（上海）股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗 潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改 制的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟 先生。立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法 实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司 会计监督委员会（PCAOB）注册登记。 截至 2024 年末，立信拥有合伙人 296 名、注册会计师 2,498 名、从业人员 总数 10,021 名，签署过证券服务业务审计报告的注册会计师 743 名。 立信 2024 年业务收入（经审计）47.48 亿元，其中审计业务收入 36.72 亿元， ...